Ernesto Rossi1, Cinzia Bagalà2, Frediano Inzani3, Emanuele Leoncini4, Chiara Brunelli3, Paola Lanza3, Michele Basso2, Gian Carlo Mattiucci5, Alessandra Cassano2, Guido Rindi3, Carlo Barone2, Giovanni Schinzari2. 1. Department of Medical Oncology, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy ernestorossi.rm@gmail.com. 2. Department of Medical Oncology, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy. 3. Institute of Anatomic Pathology, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy. 4. Section of Hygiene, Institute of Public Health, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy. 5. Department of Radiation Oncology, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy.
Abstract
BACKGROUND/AIM: In genetically engineered murine models of pancreatic ductal adenocarcinomas (PDAC), high levels of Runx3 increase the metastatic potential of cancer cells. In this study we evaluated the role of Runx3 in human pancreatic cancer. MATERIALS AND METHODS: Runx3 was retrospectively assessed by immunohistochemistry in seventy-eight tumor samples of patients who underwent surgical resection for PDCA and were followed at least for 24 months. RESULTS: Thirty-two cases resulted completely negative for Runx3; forty-six showed highly variable expression. We established an optimal cut-off value of Runx3 in predicting distant metastasis equal to 0.04. The odds ratio (ORs) for development of distant metastases at multivariate analysis for patients having Runx3 ≥0.04 was 4.26 (p=0.043) and 4.68 (p=0.032) after adjusting for residual tumor and treatment, respectively; OR for development of metastases in multiple sites was 4.28 (p=0.025) for Runx3 ≥0.04. CONCLUSION: Our results support the ability of Runx3 to contribute to the dissemination of human PDAC thus confirming the observations from murine models. Copyright
BACKGROUND/AIM: In genetically engineered murine models of pancreatic ductal adenocarcinomas (PDAC), high levels of Runx3 increase the metastatic potential of cancer cells. In this study we evaluated the role of Runx3 in humanpancreatic cancer. MATERIALS AND METHODS:Runx3 was retrospectively assessed by immunohistochemistry in seventy-eight tumor samples of patients who underwent surgical resection for PDCA and were followed at least for 24 months. RESULTS: Thirty-two cases resulted completely negative for Runx3; forty-six showed highly variable expression. We established an optimal cut-off value of Runx3 in predicting distant metastasis equal to 0.04. The odds ratio (ORs) for development of distant metastases at multivariate analysis for patients having Runx3 ≥0.04 was 4.26 (p=0.043) and 4.68 (p=0.032) after adjusting for residual tumor and treatment, respectively; OR for development of metastases in multiple sites was 4.28 (p=0.025) for Runx3 ≥0.04. CONCLUSION: Our results support the ability of Runx3 to contribute to the dissemination of human PDAC thus confirming the observations from murine models. Copyright
Authors: Sayyed K Zaidi; Andrew J Sullivan; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian Journal: Proc Natl Acad Sci U S A Date: 2002-06-11 Impact factor: 11.205
Authors: Martin C Whittle; Kamel Izeradjene; P Geetha Rani; Libing Feng; Markus A Carlson; Kathleen E DelGiorno; Laura D Wood; Michael Goggins; Ralph H Hruban; Amy E Chang; Philamer Calses; Shelley M Thorsen; Sunil R Hingorani Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban Journal: Am J Pathol Date: 2000-01 Impact factor: 4.307
Authors: D Levanon; O Brenner; V Negreanu; D Bettoun; E Woolf; R Eilam; J Lotem; U Gat; F Otto; N Speck; Y Groner Journal: Mech Dev Date: 2001-12 Impact factor: 1.882
Authors: Fiona Campbell; Richard A Smith; Philip Whelan; Robert Sutton; Michael Raraty; John P Neoptolemos; Paula Ghaneh Journal: Histopathology Date: 2009-09 Impact factor: 5.087
Authors: R Soong; N Shah; B K Peh; P Y Chong; S S Ng; N Zeps; D Joseph; M Salto-Tellez; B Iacopetta; Y Ito Journal: Br J Cancer Date: 2009-02-17 Impact factor: 7.640
Authors: Min Li; Kun Fan; Bohao Zheng; David Zekria; Tao Suo; Han Liu; Sheng Shen; Houbao Liu; Xiaoling Ni Journal: Cancer Manag Res Date: 2021-03-08 Impact factor: 3.989